Journal Options Hepatitis
Course Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, FACP
Featured Expert Commentary
Bruce R. Bacon, MD
James F. King, MD, Endowed Chair in Gastroenterology
Professor of Internal Medicine
Division of Gastroenterology and Hepatology
Saint Louis University Liver Center
Saint Louis University School of Medicine
St Louis, Missouri
Recent Articles
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Sanyal AJ, Chalasani N, Kowdley KV, et al. N Engl J Med. 2010;362:1675-1685. Capsule Summary | Expert Commentary | Abstract | Slides
Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B.
Wong VW, Wong GL, Yan KK, et al. Hepatology. 2010;51:1945-1953. Capsule Summary | Expert Commentary | Abstract | Slides
Long-term efficacy of tenofovir monotherapy for hepatitis B virus–monoinfected patients after failure of nucleoside/nucleotide analogues.
van Bömmel F, de Man RA, Wedemeyer H, et al. Hepatology. 2010;51:73-80. Capsule Summary | Expert Commentary | Abstract | Slides
Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naive, hepatitis B e antigen–positive patients receiving entecavir.
Jung YK, Kim JH, Lee YS, et al. J Clin Gastroenterol. 2010;Epub ahead of print. Capsule Summary | Expert Commentary | Abstract | Slides
Hepatic interferon-stimulated genes expression is associated with genetic variation in interleukin 28B and the outcome of interferon therapy for chronic hepatitis C.
Honda M, Sakai A, Yamashita T, et al. Gastroenterology. 2010;Epub ahead of print. Capsule Summary | Expert Commentary | Abstract | Slides
Telaprevir for previously treated chronic HCV infection.
McHutchison JG, Manns MP, Muir AJ, et al. N Engl J Med. 2010;362:1292-1303. Capsule Summary | Expert Commentary | Abstract | Slides
Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
Ferenci P, Laferl H, Scherzer TM, et al. Gastroenterology. 2010;138:503-512. Capsule Summary | Expert Commentary | Abstract | Slides
Rifaximin treatment in hepatic encephalopathy.
Bass NM, Mullen KD, Sanyal A, et al. N Engl J Med. 2010;362:1071-1081. Capsule Summary | Expert Commentary | Abstract | Slides
Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients.
Angelico F, Franicoso S, Del Ben M, et al. Aliment Pharmacol Ther. 2009;30:444-451. Capsule Summary | Expert Commentary | Abstract | Slides
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients.
Berg T, Weich V, Teuber G, et al. Hepatology. 2009;50:369-377. Capsule Summary | Expert Commentary | Abstract | Slides
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Volume 4, Issue 1
Collection
Hepatitis Journal Options – Volume 4, Issue 1
Program Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, FACP
  
- Bruce R. Bacon, MD
- Robert S. Brown, Jr., MD, MPH
- Maurizia Rossana Brunetto, MD
|
 
- Jordan J. Feld, MD, MPH
- Paul Martin, MD
- Timothy Morgan, MD
|
 
- Paul J. Pockros, MD
- Mark S. Sulkowski, MD
|
Abstract
Volume 3, Issue 3
Collection
Hepatitis Journal Options – Volume 3, Issue 3
Program Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, FACP
  
- Natalie H. Bzowej, MD, PhD
- Peter Ferenci, MD
- Michael Gale, Jr., PhD
|
  
- Stuart C. Gordon, MD
- Tarek Hassanein, MD, FACP, FACG, AGAF
- Paul Y. Kwo, MD
|
- Alessandra Mangia, MD
- Sammy Saab, MD, MPH, AGAF
|
|